Polatuzumab Vedotin (Polivy) for DLBCL - Details


( Last Updated : May 6, 2021)
Generic Name:
Polatuzumab Vedotin
Project Status:
Complete
Therapeutic Area:
Diffuse large B-cell lymphoma (DLBCL)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Polivy
Project Line:
Reimbursement Review
Project Number:
PC0227-000
NOC Date:

Details


Tumour Type:
Lymphoma
Indications:
Diffuse Large B-Cell Lymphoma (DLBCL)
Funding Request:
Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.
Review Status:
Notification to Implement Issued
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.